Moral evaluation of risk/benefit in early phase studies requires assessing the clinical promise of a candidate intervention using preclinical evidence. Yet, there is little to guide ethics committees, investigators, sponsors or other stakeholders morally charged with making these assessments (‘evaluators’). In what follows, we draw on published guidelines for preclinical study design to develop a structured process for assessing the clinical promise of new interventions. In the first step, evaluators gather all relevant preclinical studies, assess the magnitude of treatment effects and determine clinical promise in light of various threats to valid clinical inference. In the second step, evaluators adjust the assessments of clinical promise from preclinical studies by examining how other agents in the same reference class—and supported by similar evidence—have fared in clinical development. Assessments of clinical promise can then be fed into the moral evaluation of risk and benefit in early phase trials. Though our approach has limitations, it offers a systematic and transparent method for assessing risk/benefit in early phase trials of novel interventions.
- Animal Experimentation
- Clinical trials
- Research Ethics
- Scientific Research
- Stem Cell Research
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Read the full text or download the PDF:
Other content recommended for you
- Do we really know how many clinical trials are conducted ethically? Why research ethics committee review practices need to be strengthened and initial steps we could take to strengthen them
- Cell therapy for the preterm infant: promise and practicalities
- Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
- How to keep high-risk studies ethical: classifying candidate solutions
- PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
- First-in-human HIV-remission studies: reducing and justifying risk
- Combined meta-analysis of preclinical cell therapy studies shows overlapping effect modifiers for multiple diseases
- Stem cell-based therapies in neonatology: a new hope
- Efficacy of topical cannabinoids in the management of pain: a systematic review and meta-analysis of animal studies
- Regenerative medicine for neurological diseases—will regenerative neurosurgery deliver?